PPARδ binding to heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats by Sodhi, Komal et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
Summer 6-19-2013
PPARδ binding to heme oxygenase 1 promoter
prevents angiotensin II-induced adipocyte
dysfunction in Goldblatt hypertensive rats
Komal Sodhi
Marshall University, sodhi@marshall.edu
Nitin Puri
Dong Hyun Kim
Terry D. Hinds Jr.
Lance A. Stechschulte
See next page for additional authors
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Medical Biochemistry Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Sodhi K, Puri N, Kim DH, Hinds TD, Stechschulte LA, Favero G, Rodella L, Shapiro JI, Jude D, Abraham NG. PPAR? binding to
heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats. International
Journal of Obesity 2014; 38: 456–465.
Authors
Komal Sodhi, Nitin Puri, Dong Hyun Kim, Terry D. Hinds Jr., Lance A. Stechschulte, Gaia Favero, Luigi
Rodella, Joseph I. Shapiro M.D., David C. Jude, and Nader X. Abraham
This article is available at Marshall Digital Scholar: http://mds.marshall.edu/sm_bm/110
OPEN
ORIGINAL ARTICLE
PPARd binding to heme oxygenase 1 promoter prevents
angiotensin II-induced adipocyte dysfunction in Goldblatt
hypertensive rats
K Sodhi1,4, N Puri2,4, DH Kim1, TD Hinds2, LA Stechschulte2, G Favero3, L Rodella3, JI Shapiro1, D Jude1 and NG Abraham1
OBJECTIVE: Renin–angiotensin system (RAS) regulates adipogenic response with adipocyte hypertrophy by increasing oxidative
stress. Recent studies have shown the role of peroxisome proliferator-activated receptor-d (PPARd) agonist in attenuation of
angiotensin II-induced oxidative stress. The aim of this study was to explore a potential mechanistic link between PPARd and the
cytoprotective enzyme heme oxygenase-1 (HO-1) and to elucidate the contribution of HO-1 to the adipocyte regulatory effects of
PPARd agonism in an animal model of enhanced RAS, the Goldblatt 2 kidney 1 clip (2K1C) model.
METHOD: We first established a direct stimulatory effect of the PPARd agonist (GW 501516) on the HO-1 gene by demonstrating
increased luciferase activity in COS-7 cells transfected with a luciferase-HO-1 promoter construct. Sprague-Dawley rats were divided
into four groups: sham-operated animals, 2K1C rats and 2K1C rats treated with GW 501516, in the absence or presence of the HO
activity inhibitor, stannous mesoporphyrin (SnMP).
RESULTS: 2K1C animals had increased visceral adiposity, adipocyte hypertrophy, increased inflammatory cytokines, increased
circulatory and adipose tisssue levels of renin and Ang II along with increased adipose tissue gp91 phox expression (Po0.05) when
compared with sham-operated animals. Treatment with GW 501516 increased adipose tissue HO-1 and adiponectin levels (Po0.01)
along with enhancement of Wnt10b and b-catenin expression. HO-1 induction was accompanied by the decreased expression of
Wnt5b, mesoderm specific transcript (mest) and C/EBPa levels and an increased number of small adipocytes (Po0.05). These effects
of GW501516 were reversed in 2K1C animals exposed to SnMP (Po0.05).
CONCLUSION: Taken together, our study demonstrates, for the first time, that increased levels of Ang II contribute towards
adipose tissue dysregulation, which is abated by PPARd-mediated upregulation of the heme-HO system. These findings highlight
the pivotal role and symbiotic relationship of HO-1, adiponectin and PPARd in the regulation of metabolic homeostasis in
adipose tissues.
International Journal of Obesity (2014) 38, 456–465; doi:10.1038/ijo.2013.116
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INTRODUCTION
Adipose tissues are a site for energy storage and also functions as
an endocrine organ that secretes various biologically active
molecules called adipocytokines. Hyperplasia and hypertrophy of
adipocytes is central to pathological conditions such as obesity
and metabolic syndrome,1–3 conditions that are frequently
associated with chronic redox imbalances. Reactive oxygen
species (ROS) regulate the adipogenic process where
ROS-induced adipocyte hypertrophy has been observed.4–6 In
this regard, angiotensin II activates cellular oxidases and
precipitates redox imbalance.7 Angiotensin II has also been
reported to regulate adipocyte growth and differentiation along
with modulation of adipocytokine expression and release.8
Increased Ang II levels in adipocytes induce oxidative stress and
attenuate adiponectin release.4 The Goldblatt 2 kidney 1 clip
(2K1C) model is a model for reno-vascular hypertension
characterized by activation of the renin–angiotensin system
(RAS)9 whose local adipose tissue effects have recently been
reported.10 However, precise regulatory effect of Ang II on adipose
tissue is still unclear and needs further examination.
Peroxisome proliferator-activated receptor-d (PPARd), a member
of the PPAR nuclear receptor family, is a ligand-activated
transcriptional factor with a multifunctional role in lipid metabolism,
namely, to increase lipolysis, promote fatty acid catabolism and
energy expenditure in adipose tissues.11,12 PPARd forms obligate
heterodimers with the retinoid X receptor and bind to defined
PPAR elements in the promoter region of target genes. PPARd is
expressed in many tissues, including metabolically active sites such
as the liver, muscle and fat, and its role in the metabolic syndrome
is currently elucidated.12 PPARd is activated by oxidative stress and
has an important role in decreasing inflammation, apoptosis and
leukocyte adhesion. Recent studies have shown the role of PPARd
agonist in the attenuation of angiotensin II-induced oxidative stress
in vascular smooth muscles.13 Additionally, upregulation of the
antioxidant enzyme system, that is, the heme–heme oxygenase
system (HO) has also been shown to reduce Ang II-induced
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oxidative stress, with abatement of associated cardiovascular
complications. HO system comprises of two isoforms, a constitu-
tively expressed isoform called HO-2 and an inducible HO-1.14
HO-1 is stimulated by a variety of stimuli, including heavy metals,
ROS, NO, Ang II and cytokines.15–17 Induction of the HO-1 gene,
both in vivo and in cell cultures, reduces adipocyte hypertrophy
with an increase in adiponectin levels and the number of small
adipocytes, which are regarded as ‘healthy’ insulin-sensitive
adipocytes.18,19
This study examines adipose tissue effects of increased Ang II,
both in vitro and in vivo (Goldblatt’s 2K1C model). In addition, we
use this model to evaluate a possible interplay between PPARd
and HO-1 in regulating adipocyte morphology and function, as
both HO-1 and PPARd have been shown to attenuate Ang II-
induced redox imbalance and associated pathologies. In con-
textual light, the present study aims to explore the effectiveness of
a PPARd agonist in the prevention of Ang II-induced adipocyte
dysfunction and the possible interaction between PPARd and HO-
1 system in a model of enhanced oxidative stress. This novel study
corroborates the existence of a PPARd-HO-1 axis whose direct
stimulation via the administration of an exogenous PPARd agonist
induces HO-1 expression, abates RAS-associated adipocyte dys-
function and induces adipocyte remodeling with smaller adipo-
cytes while decreasing inflammation and increasing adiponectin
secretion.
MATERIALS AND METHODS
Animal treatment
All animal studies were approved by the New York Medical College
Animal Care and Use Committee in accordance with the National
Institutes of Health Guidelines for Care and Use of Laboratory Animals.
Forty, 8-week-old Sprague-Dawley rats were used in the studies.
Sprague-Dawley rats were divided into four groups: sham-operated
animals, 2K1C rats and 2K1C rats treated with GW 501516, in the absence
or presence of the HO activity inhibitor, stannous mesoporphyrin
(SnMP). All surgically altered rats were fitted with a 0.25-mm U-shaped
silver clip with an internal gap of 0.25mm around the left renal artery.
GW501516 (Enzo Life Sciences Inc., Plymouth Meeting, PA, USA) was
dissolved in dimethyl sulfoxide and suspended in 0.5% carboxymethyl-
cellulose. Immediately after surgery, GW 501516 was administered via
oral gavage daily for 3 weeks at a concentration of 3mg kg 1 body
weight. SnMP was injected intraperitoneally, three times a week at a
dose of 20mg kg 1 of body weight, for 2 weeks. Blood pressure was
measured by the tail cuff method immediately before surgery and then 3
weeks after surgery. Before the experiment, rats were all acclimatised
to the tail cuff method. Rats were placed in a heat-controlled box
(36–38 1C) for approximately 10min before applying the tail cuff. The
mean of a minimum of five measurements was obtained from each rat.
After a 6-h fast, rats were anesthetized with sodium pentobarbital
(65mg kg 1, intraperitoneally) and blood was obtained from a tail vein
for glucose measurement using a glucometer (Lifescan Inc., Miligitas, CA,
USA). At the time of killing, body weight, liver weight and visceral fat
content of all rats was measured. Blood samples were collected in
K3EDTA tubes at killing and the plasma was separated. Samples were
flash frozen in liquid nitrogen and maintained at  80 1C until assayed.
Gene reporter assay
Cos7 cells were grown to 90% confluence in 24-well plates and then
transiently transfected with expression vectors for PPARd and RXR using
Lipofectamine 2000, according to the manufacturer’s protocol. A luciferase
plasmid construct containing 15 kb of the HO-1 promoter (HO-1–15 kb-Luc
reporter; courtesy of Dr Jawed Alam) was co-transfected, as appropriate,
along with a pRL-CMV renilla reporter to normalize for transfection
efficiency. Twenty-four hours post transfection, cells were treated with
either vehicle or GW501516 (PPARd agonist) for an additional 24 h until
harvest. Cell lysates were prepared by repeated freezing and thawing in
Promega lysis buffer (Promega, Madison, WI, USA), and luciferase activity
was measured using Promega’s luciferase assay system in a Dual luciferase
plate reader (Promega).
Cell culture and differentiation into adipocytes
Frozen mouse preadipocytes (3T3L-1) were purchased from ATTC
(ATTC, Manassas, VA, USA). After thawing, 3T3L cells were resuspended
in a Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, Carlsbad,
CA, USA) supplemented with 10% heat inactivated fetal bovine serum
(FBS; Invitrogen) and 1% antibiotic/antimycotic solution (Invitrogen). The
cells were plated at a density of 1–5 106 cells per 100 cm2 dish.
The cultures were maintained at 37 1C in a 5% CO2 incubator and the
medium was changed after 48 h and every 3B4 days thereafter. When
the 3T3L cells were confluent, the cells were recovered by the addition of
0.25% trypsin/EDTA (Invitrogen). 3T3L cells (Passages 2 and 3) were plated
in a 75-cm2 flask at a density of 1–2 104 cells and cultured in DMEM with
10% FBS until 80% confluence was achieved. The medium was replaced
with adipogenic medium, and the cells were cultured for an additional
7 days as described previously.5
Cells were treated every alternate day with GW501516 (10mM), Ang II
(10mM) and SnMP (5 mM) for 7 days in mouse preadipocytes.
Effect of Ang II on adipogenesis
To measure the effect of increasing Ang II concentration on MSC-derived
adipocyte differentiation, cells were treated with 0.1, 1, 10, 100 and
1000mM of Ang II every alternate day. After 7 days, cells were stained with
Oil Red O solution to study adipogenesis.
Oil Red O staining
Lipid droplets were detected by Oil red O staining. For Oil Red O staining,
0.21% Oil Red O in 100% isopropanol (Sigma-Aldrich, St Louis, MO, USA) was
used. Briefly, mouse preadipocytes were fixed in 10% formaldehyde, washed
in Oil-red O for 10min, rinsed with 60% isopropanol (Sigma-Aldrich), and the
Oil red O eluted by adding 100% isopropanol for 10min and optical density
measured at 490 nm, for a 0.5-sec reading. Mouseb preadipocytes were
measured by Oil red O staining (optical density¼ 490nm) after day 7.
Determination of adipocyte size and number
Visceral adipose tissue was collected from all the groups and prepared for
morphological analysis, as previously described.20 Samples were fixed in
4% paraformaldehyde for 24 h, cut into small pieces and embedded in
paraffin for histological analysis. The samples were cut by microtome
(5mM thick), mounted on D-polylisinated glass slides, deparaffinized in
xylene and stained with haematoxylin and eosin for the evaluation of
adipocyte size. Each sample was examined and evaluated for
the adipocyte size and number using an optical microscopy ( 200
magnification). Specifically, for each animal 100 adipocytes from different
hematoxylin–eosin-stained sections were analyzed by determining indivi-
dual adipocyte areas (mM2) using an image analyzer (Image Pro Plus, Milan,
Italy). The data were pooled to represent a mean value and a statistical
analysis was applied to compare the results obtained from the different
experimental groups with a statistical significance set at Po0.05. The data
were presented as the mean±s.d.
Western blot analysis of HO-1, adiponectin, gp phox91 and
adipogenic markers
Frozen adipose tissue was pulverized under liquid nitrogen and placed in a
homogenization buffer comprising (mmol l 1): 10 phosphate buffer, 250
sucrose, 1 EDTA, 0.1 phenylmethanesulfonylfluoride, and 0.1% v/v tergitol,
pH 7.5. Homogenates were centrifuged at 27 000 g for 10min at 4 1C. The
supernatant was isolated, and protein levels were assayed (Bradford
Method). The supernatant was used for the determination of HO-1, gp
phox91, adiponectin, Pref-1, fatty acid synthase, Wnt10b, Wnt5b, b-catenin,
mest and CEBPa. Immunoblotting was performed in visceral adipose tissue
as previously described.19,21 b-Actin was used to ensure adequate sample
loading for all western blots.
Cytokines, adiponectin, Ang II, renin and lipid profile
measurements
The plasma levels of interleukin (IL)-6, monocyte chemotactic protein-1
(MCP-1) and the high molecular weight (HMW) form of adiponectin
were determined using an enzyme-linked immunosorbent assay
(ELISA) as previously described.4,21 Angiotensin II and renin was
measured in plasma and visceral adipose tissues using an ELISA assay
(Assay Gate, Inc., Ijamsville, MD, USA). Triglycerides and total low-density
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lipoprotein levels are measured in plasma using an ELISA assay
(Assay Gate, Inc.).
Quantitative real-time PCR analysis
Total RNA was extracted from liver tissues using 5-Prime PerfectPure RNA
Tissue Kit (Fisher Scientific Company, LLC, Waltham, MA, USA). Total RNA
was read on a NanoDrop 2000 Spectrophotometer (Thermo Scientific,
Wilmington, DE, USA) and cDNA was synthesized using iScript cDNA
Synthesis kit (Bio-Rad, Hercules, CA, USA). PCR amplification of the cDNA
was performed by quantitative real-time PCR using qPCR Core kit for SYBR
Green I (Applied Biosystems, Grand Island, NY, USA). The thermocycling
protocol consisted of 10min at 95 1C, 40 cycles of 15 s at 95 1C, 30 s at 60 1C
and finished with a melting curve ranging from 60 to 95 1C to allow
distinction of specific products. Primers were designed specific to each
gene using Primer Express 3.0 software (Applied Biosystems). Normal-
ization was performed in separate reactions with primers to 18S mRNA
(50-TTCGAACGTCTGCCCTATCAA-30 and 50-ATGGTAGGCACGGCGACTA-30).
Statistical analysis
Data are expressed as means±s.e.m. Significance of difference in
mean values was determined using one-way analysis of variance followed
by the Newman–Keul’s post hoc test. Po0.05 was considered to be
significant.
RESULTS
Effect of the PPARd agonist on adipogenesis in mouse
preadipocytes
To study the effects of Ang II on adipogenesis, in vitro, 3T3L1 cells
were exposed to Ang II in a dose-dependent manner. At 10 mM,
Ang II increased adipogenesis in mouse preadipocytes, measured
as the relative absorbance of Oil Red O on day 7 of the experiment
(Figure 1a; Po0.05); follow-up in vitro experiments were
performed with 10 mM of Ang II. We then studied the effects of
the PPARd agonist on adipogenesis in mouse preadipocytes, in
the absence or in the presence of Ang II (Figure 1b). Our results
show that concurrent administration of PPARd agonist signifi-
cantly (Po0.05) decreased adipogenesis in preadipocytes treated
with Ang II; this effect was not seen in experiments conducted
with SnMP, the HO inhibitor (Figure 1b; Po0.05).
Effect of the PPARd agonist on body weight and the metabolic
profile
As shown in Table 1, animals with clipped kidneys have body
weight similar to sham-operated animals. Liver weight, plasma
glucose, serum triglycerides and total low-density lipoprotein
levels were also not dissimilar between the two groups. Treatment
Figure 1. (a) Effect of increasing Ang II concentrations on adipogenesis in mouse preadipocytes. Lipid droplet area was measured as the
relative absorbance of Oil Red O at day 7 after inducing adipogenesis as described in Materials and Methods (mean±s.e., *Po0.05 vs vehicle;
n¼ 6). (b) Effect of the PPARd-agonist (GW501516) and Ang II on adipogenesis in mouse preadipocytes. Adipogenesis was measured as the
relative absorbance of Oil Red O at day 7 after inducing adipogenesis as described in Methods and procedures (mean±s.e., *Po0.05 vs
vehicle; n¼ 6).
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with the PPARd agonist, alone or in combination with SnMP,
did not affect these anthropometric and general metabolic
parameters in Goldblatt’s hypertensive rats.
Effect of the PPARd agonist on plasma renin and Ang II levels
Quantitative analysis, performed on the plasma from Goldblatt’s
2K1C and sham-operated animals, showed significant elevation of
plasma renin (Po0.05) and Ang II levels in rats with a clipped
kidney (Figures 2a and b). Treatment with the PPARd
agonist significantly decreased renin (Po0.05) and Ang II
levels (Po0.05) in these rats, an effect reversed by the
administration of SnMP (Po0.05). We measured blood pressure
in this animal model of renovascular hypertension and, as
expected, systolic blood pressure was increased in 2K1C rats
as compared with sham animals (167.3±10.8mmHg vs
124.1±9.4mmHg, respectively; Po0.05). Treatment with the
PPARd agonist significantly reduced the levels of systolic blood
pressure in the 2K1C rats (135±8.9mmHg; Po0.05 vs 2K1C); this
was abolished in animals also treated with SnMP (159±8.4mm
Hg; Po0.05 vs 2K1CþGW).
Effect of the PPARd agonist on plasma inflammatory cytokines and
adiponectin levels
The Goldblatt 2K1C model is associated with systemic inflamma-
tion, and this was examined in the current study. Plasma IL-6 and
MCP-1 levels were greater in the 2K1C rats when compared with
sham-operated rats (Figures 2c and d; Po0.05). The PPARd agonist
(Po0.05) decreased plasma IL-6 and MCP-1 levels and this was
prevented in animals also treated with SnMP (Po0.05; Figures 2c
and d). One of the established markers of dysfunctional adipose
tissues is the attenuation of plasma adiponectin levels. Goldblatt’s
2K1C rats displayed reduced plasma adiponectin levels when
compared with sham animals (Figure 2e; Po0.05). Plasma
adiponectin levels were increased in 2K1C rats treated with the
PPARd agonist (Po0.05). SnMP prevented the increase in
adiponectin levels when compared with animals administered
the PPARd agonist alone (Figure 2e).
Effect of the PPARd agonist on adipose tissue renin and Ang II
levels and on the marker of oxidative stress
Complementary results show that visceral adipose tissue renin
was increased in Goldblatt 2K1C model, a model of enhanced RAS,
as compared with control animal (Figure 3a; Po0.05). Treatment
with the PPARd agonist decreased renin levels (Po0.05) and this
effect was reversed by administration of PPARd agonist and SnMP.
Similarly, Ang II levels in visceral adipose tissue were increased in
2K1C1 rats as compared with control animals (Po0.05). The PPARd
agonist decreased Ang II levels, and this effect was reversed by the
concurrent administration of SnMP (Figure 3b). Oxidative stress
was assessed in visceral adipose tissues by the measurement of gp
phox 91 protein expression level, which was increased in 2K1C rats
when compared with control animals (Figure 3c; Po0.05). PPARd
agonist decreased the expression of gp phox 91 (Po0.05) while
SnMP prevented this decrease (Po0.05).
Table 1. Anthropometric and general metabolic parameters
Sham 2K1C 2K1CþGW 2K1CþGWþ SnMP
Body weight (g) 324.75±7.88 343.75±14.68 337.8±14.31 346.8±12.00
Liver weight (gms) 11.65±0.75 11.95±0.80 12.90±0.99 12.52±0.88
Glucose, fasting (mgdl 1) 117±6.1 121±3.9 114±7.7 118±4.2
TGs (mM) 0.67±0.1 0.86±0.08 0.76±0.04 0.97±0.15
LDL (mgdl 1) 30.42±7.3 55.80±11.82 34.17±4.68 39.51±3.43
Abbreviations: 2K1C, 2 kidney 1 clip; LDL, low-density lipoprotein; SnMP, stannous mesoporphyrin; TG, triglyceride. Values are mean±s.e. N¼ 5 for each group.
Figure 2. (a, b) Effects of the PPARd-agonist in 2K1C animals on plasma renin and Ang II levels; results are means±s.e., n¼ 6/group. (a) Plasma
renin; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. (b) Plasma Ang II; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs
2K1CþGW. (c–e) Effects of the PPARd-agonist in 2K1C animals on plasma cytokines and adiponectin levels; results are means±s.e.,
n¼ 6/group. (c) Plasma IL-6; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. (d) Plasma MCP-1; *Po0.05 vs control, #Po0.05 vs
2K1C,þ Po0.05 vs 2K1CþGW. (e) Plasma adiponectin levels; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW.
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Effect of the PPARd agonist on adipogenesis and visceral fat
content
Histological examination of the visceral adipose tissues revealed
that cross-sectional area of the adipocytes from 2K1C rats was
significantly higher when compared with control rats (Figure 4a;
Po0.05). The adipocyte area is reduced in rats treated with
the PPARd agonist and SnMP reverses this effect, indicating
the interactive role of PPARd-HO-1 in regulating adipocyte
hypertrophy and lipid accumulation (Po0.05). Apart from
affecting size, adipocyte number was also modulated in 2K1C
Figure 3. Effects of the PPARd-agonist on adipose tissue renin and Ang II levels, and on the marker of oxidative stress; results are means±s.e.,
n¼ 6/group. (a) Adipose tissue renin; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. (b) Adipose tissue Ang II; *Po0.05 vs
control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. (c) Western blot and densitometry analysis of gp phox 91expression; *Po0.05 vs control,
#Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. Data are shown as mean band density normalized to b-actin.
Figure 4. (a) Hematoxylin–eosin staining of visceral adipose tissue and quantitative analysis of adipocyte size, expressed in mm2, in 2K1C
animals—treated with and without GW 501516 or GW 501516þ SnMP. Results are means±s.e.; *Po0.05 vs control, #Po0.05 vs 2K1C,
þ Po0.05 vs 2K1CþGW. (b) The graph shows number of adipocytes in 2K1C animals—treated with and without GW 501516 or GW
501516þ SnMP. * Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. (c) Effects of the PPARd-agonist on visceral fat in 2K1C
animals—treated with and without GW 501516 or GW 501516þ SnMP. Results are means±s.e., n¼ 6/group; *Po0.05 vs control, #Po0.05 vs
2K1C,þ Po0.05 vs 2K1CþGW.
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rats, showing a reduction, when compared with the control
animals (Figure 4b; Po0.05). The number of adipocytes increased
in rats treated with the PPARd agonist, and treatment with SnMP
decreased this adipocyte number (Po0.05). Though the body
weight of rats did not change among the different groups
(Table 1), visceral fat content was significantly higher in 2K1C rats
when compared with the control animals (Figure 4c; Po0.05).
2K1C rats treated with the PPARd agonist showed a significant
reduction in visceral fat content and the concurrent administration
of SnMP produced an increase in visceral fat mass (Figure 4c).
We also examined the hepatic lipid-oxidation pathways to
ascertain their role in bringing about adipose tissue changes in the
2K1C rats as compared with the sham-operated rats. Rats with a
clipped kidney had levels of carnitine palmitoyltransferase 1A
(CPT1a) and mitochondrial uncoupling protein 2 (UCP2) mRNA not
dissimilar from the controls (CPT1a: sham—1.41±0.07 vs 2K1C—
1.18±0.15; UCP2: sham—1.38±0.08 vs 2K1C—1.13±0.10). It is
noteworthy, however that treatment with the PPARd agonist
increased (Po0.05) gene expression of both CPT1a and UCP2 in
the 2K1C rats (CPT1a: 2K1CþGW—2.45±0.06; UCP2: 2K1C—
2.15±0.08; Po0.05 vs 2K1C). SnMP blocked this stimulatory effect
of the PPARd agonist (CPT1a: 2K1CþGWþ SnMP—1.70±0.10;
UCP2: 2K1CþGWþ SnMP—1.67±0.11; Po0.05 vs 2K1CþGW).
Effect of PPARd agonist on adipogenic markers and adiponectin
expression in visceral adipose tissue
Our next set of experiments examined possible mechanisms
involved in RAS-dependent stimulation of visceral adiposity.
We first studied the levels of Wnt10b, b-catenin and adiponectin
to see whether they could account for the decrease in fat content
in adipose tissues of 2KIC rats treated with the PPARd agonist.
Wnt10b and b-catenin levels decreased in 2K1C rats as compared
with control animals (Figures 5a and b respectively; Po0.01).
Administration of the PPARd agonist increased the Wnt10b and
b-catenin expression; SnMP blocked this effect (Po0.05). Activation
of the Wnt-signalling cascade promotes a lower differentiation
state of pre-adipocytes,22 and this was tested in our study via pre-
adipocyte factor 1 (pref1) expression analysis (Figure 5c). Pref1 is
an adipocyte marker, expressed abundantly in pre-adipocytes.
Animals with a clipped kidney expressed lower levels of pref1
(Po0.05). Pref1 expression was rescued by the PPARd agonist
(Po0.05), an effect blocked by SnMP (Po0.05). Additionally,
western blot analysis of adiponectin levels showed a significant
reduction (Po0.05) in 2K1C rats as compared with control animals
(Figure 5d); Po0.05. The concurrent administration of the PPARd
agonist increased (Po0.05) adiponectin expression and SnMP
decreased this effect. These data suggest that an increase in
PPARd-HO-1 axis improves adipocyte function and reduces
adiposity through upregulation of adipocyte-protective adiponectin
and activation of Wnt10b and b-catenin pathway.
Effect of PPARd agonist on adipogenic markers in visceral adipose
tissue
Experiments studying positive regulators of lipid accumulation
and adipogenesis were examined next. Our results showed that
positive regulators of adipogenesis mest, C/EBPa and Wnt5b levels
Figure 5. Effects of the PPARd-agonist on adipogenic markers and adiponectin expression in adipose tissue in 2K1C animals—treated with and
without GW 501516 or GW 501516þ SnMP. (a, b) Western blot and densitometry analysis of Wnt10b and b-catenin expression respectively;
*Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. Results are means±s.e., n¼ 6/group; data are shown as mean band density
normalized to b-actin. (c) Western blot and densitometry analysis of pref1 expression; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs
2K1CþGW. Results are means±s.e., n¼ 6/group; data are shown as mean band density normalized to b-actin. (d) Western blot and
densitometry analysis of adiponectin expression; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. Results are means±s.e.,
n¼ 6/group; data are shown as mean band density normalized to b-actin.
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were all increased significantly in 2K1C rats as compared with
control animals (Figures 6a–c, respectively; Po0.05). The
concurrent administration of the PPARd agonist decreased mest,
C/EBPa and Wnt5b expression, and this effect was increased by
SnMP treatment in 2K1C animals (Po0.05). Additionally, fatty acid
synthase expression (Figure 6d; Po0.05) was elevated in rats with
a clipped kidney. PPARd agonist treatment blocked this increase
(Po0.05), which was restored when animals were co-treated with
SnMP (Po0.05).
Effect of PPARd agonist on HO-1 levels in visceral adipose tissue
We evaluated the proposed interplay between PPARd and HO
systems in the 2K1C animal model. Western blot analysis showed
a significant increase in HO-1 expression (Po0.05) in the visceral
adipose tissue of 2K1C rats treated with the PPARd agonist, as
compared with the 2K1C rats without treatment (Figure 7a).
Furthermore, our results showed that the concurrent administra-
tion of SnMP also increased HO-1 expression. These findings
confirm our previous results with SnMP, which induced a
significant increase in HO-1 expression but is a potent inhibitor
of HO activity.9 This effect of SnMP prevents heme degradation
and inhibits formation of HO products, that is, CO and biliverdin.
To study the potential mechanistic link between PPARd and
HO-1, we transiently transfected the HO-1 promoter luciferase
construct into Cos 7 cells. Overexpression of PPARd cDNA and
treatment with its agonist GW501516 significantly increased HO-1
promoter activity (Figure 7b; Po0.05). In addition, our results
show that there was no significant increase in HO-1 promoter
activity in the absence of PPARd cDNA overexpression or with
GW501516, suggesting that HO-1 is a PPARd-target gene.
DISCUSSION
Angiotensin II induces oxidative stress and contributes to various
pathological conditions, including insulin resistance and the
metabolic syndrome.8,23 In this regard, recent reports have
indicated that inhibitors of the RAS attenuate oxidative stress
and improve the metabolic profile in various animal models.24
However, evidence linking Ang II with adipocyte size and
function is scarce, thereby prompting the present study. Two
complimentary lines of evidence highlight the first key finding of
this study,that is, a stimulatory effect of Ang II on adipocyte size
and lipid accumulation. First sets of experiments demonstrate a
dose-dependent increase in lipogenesis: in rodent preadipocytes
with exogenous Ang II. Complementary in vivo studies reveal that
elevation of endogenous Ang II levels also lead to adipocyte
hypertrophy and visceral adiposity. Redox imbalance has been
shown to increase adipogenesis5 that is characterized by
adipocyte hypertrophy and dysfunction.5 Goldblatt’s 2K1clip
animals are an established model of reno-vascular hypertension
where upregulated RAS precipitates redox imbalance and
oxidative stress.9 These animals exhibit high blood pressure with
increased plasma levels of renin and Ang II, including in adipose
tissues. Increased visceral adiposity was evident in these animals
in spite of less than significant change in their body and liver
weight, blood glucose, serum triglycerides and low-density
lipoprotein levels. This suggests that Ang II is directly
responsible for the adipocyte hypertrophy that appears to be
defined by its ability to modulate redox balance. Relevant to these
findings, Ang II-induced increase in adiposity was characterized
by depleted proliferation and enhanced lipid accumulation by
visceral adipocytes: morphological characteristics frequently
accompanied by adipocyte dysfunction.
Figure 6. Effects of the PPARd-agonist on adipogenic marker expression in adipose tissue in 2K1C animals—treated with and without GW
501516 or GW 501516þ SnMP. (a–d) Western blot and densitometry analysis of mest, C/EBPa, Wnt5b and fatty acid synthase (FAS) levels,
respectively; *Po0.05 vs control, #Po0.05 vs 2K1C,þ Po0.05 vs 2K1CþGW. Results are means±s.e., n¼ 6/group; data are shown as mean
band density normalized to b-actin.
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Increased circulating levels of inflammatory cytokines, and
reduced adiponectin levels, both in the plasma and in the adipose
tissues, substantiate Ang II-induced dysfunctional adipogenesis in
the 2K1clip rats. Adiponectin is a cytoprotective adipokine used as
a marker of adipocyte function.3 Attenuation of adiponectin levels
is frequently associated with enlarged, hypoxic adipocytes, which
also demonstrate increased inflammatory infiltration.25 These
morpho-physiological alterations of the adipocytes are the
hallmarks of obesity and metabolic syndrome.22,26 Association of
these functional perturbations of adipocytes with elevated levels
of Ang II implicates its role in bringing about these dysfunctions.
Redox-dependent modulation of Wnt10b/b-catenin (the cano-
nical pathway) is an effect that underlies increased lipid
accumulation and hypertrophic adipogenesis; this is commonly
observed in clinico-pathological scenarios associated with
oxidative stress.22,25 Wnt10b is an endogenous regulator of
adipogenesis that functions as a ‘switch’ that retards adipocyte
differentiation and maturation into lipid-laden cells. Activation of
Wnt10b contributes to the inactivation/phosphorylation of
glycogen synthase kinase-3b and, consequently, elevated level
of b-catenin (Figure 8); it is the molecular node of the canonical
Wnt signaling pathway.27 Conversely, Wnt5b, another component
of the Wnt family, stimulates adipogenesis by inhibiting the
b-catenin and the Wnt-signaling cascade.28 Consistent with these
findings, we found that the Wnt10b and b-catenin protein
expression were downregulated and that the Wnt5b protein
levels were increased in 2K1clip rats. Wnt10b maintains adipocytes
in a reduced state of differentiation22 as evident in our study by
the expression of pref1. Pref1 is employed as a marker for
adipocyte differentiation; abundant in pre-adipocytes, while the
expression declines progressively as they mature and accumulate
lipid droplets. Rats with overexpression of the RAS demonstrated
attenuation of the Wnt-signalling cascade along with lower levels
of pref1 protein. These observations, in conjunction with the
morphological characteristics of the visceral adipose tissues,
implicate RAS-mediated promotion of adipocyte growth and
differentiation in these animals. Supportive evidence in this
direction shows that RAS-induced dysfunctional adipogenesis is
accompanied by increased expression of adipogenic regulators—
mest and CCAAT/enhancer binding protein (C/EBPa). An increase
in Wnt/b-catenin signaling inhibits C/EBPa and mest levels, which
are expressed during adipogenesis and have a crucial role in the
transcriptional regulation of adipocyte genes.25
The redox-dependent increase in adipogenesis and adipocyte
hypertrophy is attenuated by exogenous antioxidants.22 In this
Figure 8. A schematic summary of our hypotheses and obtained
results. Angiotensin II, via redox-dependent mechanisms, promotes
adipocyte growth and lipid accumulation. This involves the
suppression of the Wnt-canonical pathway and leads to dysfunc-
tional hypertrophic adipogenesis—characterized by increased visceral
adiposity, increased inflammation and decreased adiponectin
levels. A synthetic PPARd-agonist binds to and activates the HO-1
promoter, with increased HO-1 expression as a consequence.
Activation of this pathway stimulates the Wnt-canonical signaling
cascade in adipose tissues, subjected to higher levels of Ang II and
oxidative stress. Consequentially, preadipocyte maturation and lipid
accumulation is retarded, leading to an increased number of smaller
adipocytes with improved adipocytokine profile. Thus, PPARd-
agonist-mediated HO-1 activation prevents oxidative stress and
associated dysfunctional adipogenesis in animals with an overactive
renin–angiotensin system.
Figure 7. (a) Effect of PPARd-agonist on HO-1 expression in adipose tissue in 2K1C animals—treated with and without GW 501516 or GW
501516þ SnMP. Western blot and densitometry analysis of HO-1 levels; *Po0.05 vs control, #Po0.05 vs 2K1C. Results are means±s.e.,
n¼ 6/group; Data are shown as mean band density normalized to b-actin. (b) HO-1 promoter activity, as determined in Cos 7 cells by the
luciferase assay. ***Po0.05 vs without PPARd; **Po0.05 vs with PPARd but without GW.
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regard, PPARd—a ligand-activated transcription factor—regulates
inflammation, energy homeostasis and reduces oxidative stress.29
The second key finding presented in this study shows that a
synthetic PPARd agonist, GW501516, attenuates Ang II-mediated
increase in adipogenesis. Although the biological roles of
PPARa/PPARg in modulating metabolic homeostasis are well
established,30 contributions of PPARd to this process remain
unclear. Our results show that the pro-adipogenic effects of AngII,
both in vitro and in vivo, are prevented by treatment with a PPARd
agonist, manifest by an improvement in adipocyte function and
an abatement of the inflammatory response. A concomitant
attenuation in adipose tissue oxidative stress and adiponectin
rescue by GW501506 underscores the ability of PPARd activation
to restore redox balance. This could, in turn, contribute towards
the restoration of adipose tissue abnormalities observed in a
setting of elevated levels of AngII. The patho-physiological
recovery, in animals treated with a PPARd agonist, was
accompanied by the rescue of the Wnt-canonical pathway that,
in turn, retards adipocyte maturation into large lipid-laden cells.
PPARd agonist-induced effects on adipocyte differentiation are
embodied by the increased expression of pre-adipocyte marker—
pref1. In addition, the observed suppression of pro-adipogenic
regulators, mest1 and C/EBPa, support the hypothesis that
activation of PPARd via an exogenous synthetic agonist leads to
the attenuation of lipid accumulation and adipocyte hypertrophy.
These results are bolstered with reports characterizing increased
lipolysis and reduced adiposity in transgenic animals treated with
the PPARd agonist.12
Although 2K1C animals have similar hepatic lipid oxidation as
their sham-operated counterparts, PPARd agonist did induce these
biochemical processes in the treated animals. This may be one of
the contributing factors towards the agonist-induced attenuation
of adiposity, in the in vivo setting. These results are unsurprising,
as the PPARs have been shown to modulate lipid-oxidation
pathways in models of diet-induced obesity.12,31 What was
unexpected was the failure of this agonist to affect the
metabolic profile of the animals in our study. Despite reducing
visceral adiposity and inflammation, the PPARd agonist had no
effect on the metabolic profile of the treated animals. These
observations, while unexplained by the study, lend themselves to
a few hypotheses: firstly, enhanced adiposity in these animals was
not initiated by dietary alterations, rather by induction of tissue
oxidative stress; it is also possible that a more chronic study with
or without additional dietary modifications may allow a better
understanding of the patho-physiological mechanisms involved in
the redox-initiated adipogenic processes.
The heme-HO system has therapeutic potential in clinico-
pathological conditions frequently associated with chronic
oxidative stress.17,19 That AngII-dependent cardio-vascular
pathologies in the 2k1clip model of hypertension are rescued in
animals with increased levels of HO1 is evidence of the ability
of this antioxidant system to reverse the ROS-dependent effects of
AngII.9,17,32 In light of this evidence, we examined the role
of transcriptional stimulation of HO1 by the PPARd agonist, and its
role in restoring adipocyte structure and function in models with
elevated AngII. The third key finding of this study shows that the
PPARd agonist-mediated rescue of effects of AngII on adipose
tissues is reliant upon activation of the heme-HO system. Multiple
lines of evidence support this conclusion: firstly, attenuation
of visceral adiposity and improvement in adipocyte function,
observed in animals with clipped kidney and treated with
GW501516, was paralleled by upregulation of HO1. Secondly,
morpho-physiological rescue of the adipose tissues by the PPARd
agonist, both in vitro and in vivo, was prevented in a setting where
HO activity is blocked. And finally, stimulation of HO1 promoter by
the PPARd-agonist implicates PPARd binding to the HO promoter.
Further supporting evidence to the involvement of the heme-HO
system is provided by recovery of the Wnt-canonical pathway in
animals treated with the PPARd agonist. Previous reports have
shown the stimulatory effects of heme-HO on Wnt10b signaling,22
and we have evidence linking this effect of HO-1 to its
anti-adipogenic properties (unpublished work).
To conclude as represented in the schematic (Figure 8), we
show here that AngII has a stimulatory effect on adipogenesis and
adipocyte lipid accumulation, with a concomitant decline in
adipocyte function, as evidenced by the downregulation of the
protective adipokine—adiponectin. These effects of AngII
contribute towards enhanced visceral adiposity in an animal
model displaying elevation of the RAS. Suppression of the
Wnt-canonical-signaling pathways with a concomitant increase
in the pro-adipogenic regulators, such as mest, C/EVBPa and the
fatty acid synthase, appear to underlie the effects of Ang II. An
exogenous PPARd agonist suppresses the AngII-induced dysfunc-
tional adipogenesis and lipid accumulation, while stimulating
the Wnt-canonical pathway. Also contributing to this effect is the
upregulation of the hepatic lipid-oxidation processes by the
PPARd agonist. These actions of the PPARd agonist are, in turn,
reliant upon the transcriptional activation of the heme-HO system.
Antiredox properties of the HO system underlie, at least partly, the
therapeutic benefits obtained from GW501506.
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